Emcure Pharmaceuticals Rises 2.29% After US FDA Clears Gujarat Facility Without Observation
By Shishta Dutta | Published at: Oct 10, 2025 05:39 PM IST
Pune, October 10, 2025: Shares of Emcure Pharmaceuticals Ltd (NSE: EMCURE, BSE: 544210) surged today, rising 2.29% to ₹1,427.70 around 2:00 PM before settling slightly lower to close at ₹1,420.10, up 1.74% from the previous day’s close. The rally follows the company’s announcement of a successful US FDA inspection at its Kadu manufacturing facility in Gujarat, with no observations reported.
The inspection, conducted from October 6 to October 10 as part of a routine surveillance, underscores Emcure’s commitment to good manufacturing practices and adherence to global compliance standards.
Emcure Pharmaceuticals Ltd, based in Pune, is a leading integrated pharmaceutical company engaged in manufacturing, developing, and marketing a diverse portfolio of branded and generic formulations. Listed on July 10, 2024, the company continues to build its global presence across multiple therapeutic areas.
Key Market Data
The stock closed at ₹1,420.10, up ₹24.30 or 1.74% from the previous close of ₹1,395.80, after trading between ₹1,384.20 and ₹1,435.00 during the session. Total traded volume stood at 0.56 lakh shares, with a turnover of ₹7.98 crore and a VWAP of ₹1,414.10. The company’s market capitalization reached ₹27,056.11 crore, while the free-float market cap stood at ₹3,591.18 crore. The stock continues to trade comfortably within its 52-week range of ₹889.00 to ₹1,532.95.
REF: https://nsearchives.nseindia.com/corporate/EMCURE_10102025134240_EPLIntimationUSFDAInspection.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
